Why This Medicare Rate Decision Matters
Health insurer stocks surged dramatically this week. The trigger was a major policy reversal by the federal government on Medicare Advantage payment rates. After months of industry anxiety over a near-flat proposed increase, the Centers for Medicare and Medicaid Services (CMS) delivered a far more generous final figure for 2027.
The announcement marked a turning point for an industry that has faced mounting pressure from rising medical costs and federal cost-cutting efforts. Consequently, shares of the nation’s largest managed-care companies jumped sharply in both after-hours and premarket trading. Investors, analysts, and health plan executives broadly welcomed the news as a sign of renewed regulatory stability.
What CMS Finalized for 2027
The 2.48% Base Rate Increase
CMS finalized a 2.48% average payment rate increase for Medicare Advantage plans in 2027, translating to more than $13 billion in additional payments to private insurers. Furthermore, when accounting for estimated risk score trends driven by population changes and coding practices, the effective increase amounts to 4.98%.
This outcome stands in sharp contrast to what the agency initially floated. In January, CMS had proposed a near-flat 0.09% hike — a proposal that rattled markets and drew an outcry from the industry. Therefore, the jump from 0.09% to 2.48% represents a significant policy recalibration in favor of the managed-care sector.
A Reversal from January’s Proposal
The Trump administration finalized a 2027 payment rate increase to privately run Medicare plans that was far bigger than initially proposed — a boost to health insurer stocks and seniors whose out-of-pocket costs may end up lower than feared.
The decision also reflects the industry’s successful lobbying effort. The primary takeaway for investors is clear: the federal government remains committed to the Medicare Advantage model, and the industry’s data-driven arguments still carry significant weight in Washington.
How Insurer Stocks Responded
UnitedHealth Group Leads the Rally
Industry leader UnitedHealth’s stock jumped as much as 10% — the most intraday since August. The company’s diversified business model, which includes the Optum health services arm, had provided some buffer against earlier regulatory uncertainty. Yet the finalized rate still delivered a substantial boost. The finalized rates added an estimated $20 billion in market value to the healthcare giant, as investors recalibrated their 2027 earnings-per-share estimates.
Humana Sees Biggest Single-Day Gain
Humana, which operates as a pure-play insurer with a heavy concentration in Medicare Advantage, emerged as the day’s clear winner. Shares surged over 11% in early Tuesday trading, as the 2.48% hike directly eases the margin pressure that has dogged the company for the past two fiscal years.
Additionally, UnitedHealth’s annual earnings are expected to rise 8% this year and are projected to spike another 13% in FY27. Both companies carry a Zacks Rank #3 (Hold), though upward EPS revisions may follow.
CVS Health and Others Rally Too
CVS Health Corp. gained as much as 6.9%. CVS owns Aetna, one of the largest Medicare Advantage operators in the country. After a difficult 2025 characterized by fluctuating Star Ratings and medical cost concerns, the generous 2027 rate hike provides Aetna with the flexibility to compete more aggressively in the upcoming open enrollment period.
Beyond these major players, the rally extended across the broader sector. Alignment Healthcare surged 14.46%, Astrana Health rose 5.42%, and Oscar Health added 1.25%.
Risk Adjustment Changes Explained
Retaining the 2024 Risk Model
CMS also made a key technical decision alongside the rate announcement. The agency will continue using the 2024 MA risk adjustment model for 2027, giving the MA market more time to adjust to the recently completed phase-in of that model. This move was widely regarded as another win for the industry, since adopting the newer 2023-based model would have complicated reimbursement calculations.
Excluding Unlinked Chart Review Diagnoses
However, CMS did finalize one notable risk adjustment change. Beginning in 2027, diagnosis information from unlinked chart review records — those not associated with a specific patient encounter — will be excluded from risk score calculations, with an exception for beneficiaries who switch between MA organizations.
Additionally, CMS finalized updates to the Part D risk adjustment model to account for Inflation Reduction Act changes and reflect more current costs. These adjustments signal that while the agency showed flexibility on rates, it remains committed to reducing reimbursement gaming.
What Analysts Are Saying
A Better-Than-Expected Outcome
Wall Street reacted with measured optimism. Mizuho healthcare specialist Jared Holz noted that the rate increase is “certainly better” than the Trump administration’s initial proposal. He added that the boost may help companies expand margins in 2027, provided they continue reducing benefits and managing expenses effectively.
Improved Revenue Visibility
From a broader investment perspective, analyst Ryan Daniels wrote that CMS and the administration were willing to listen to industry participants and ultimately updated the model to afford stronger 2027 MA rates. These changes improve plan revenue visibility and ease concerns tied to earlier policy proposals.
Moreover, CMS Administrator Dr. Mehmet Oz stated that Medicare Advantage and Part D should work for the people who rely on them. This framing suggests the administration views the higher rate as a way to protect both insurer viability and senior member benefits simultaneously.
What This Means for Seniors
More Than Half of Medicare Beneficiaries Are in Advantage Plans
The scale of this decision extends well beyond Wall Street. More than half of Medicare beneficiaries are enrolled in Advantage plans, drawn by lower monthly premiums and extra benefits not covered by traditional Medicare. Therefore, any shift in payment rates has a direct downstream effect on plan design, benefit offerings, and out-of-pocket costs for millions of older Americans.
Lower Costs and Better Benefits Possible
When insurers receive higher reimbursements, they gain flexibility to maintain or expand the supplemental benefits that attract members to Advantage plans — such as dental, vision, and hearing coverage. Consequently, seniors may see less benefit erosion in the 2027 plan year than earlier policy signals had suggested.
Chris Klomp, director of Medicare and a senior adviser at the Department of Health and Human Services, stated that the goal is to ensure money spent on Medicare flows directly to better care and more access for seniors, rather than to administrative waste or gaming of the system. As a result, the administration framed the finalized rate as a pro-senior policy move, even as it boosted insurer stocks.
